HuGE Literature Finder
Records 1-4
A phase I study of foretinib plus erlotinib in patients with previously treated advanced non-small cell lung cancer: Canadian cancer trials group IND.196.
Oncotarget 2017 Sep 8 (41): 69651-69662. Leighl Natasha B, Tsao Ming-Sound, Liu Geoffrey, Tu Dongsheng, Ho Cheryl, Shepherd Frances A, Murray Nevin, Goffin John R, Nicholas Garth, Sakashita Shingo, Chen Zhuo, Kim Lucia, Powers Jean, Seymour Lesley, Goss Glenwood, Bradbury Penelope |
A phase I study of foretinib plus erlotinib in patients with previously treated advanced non-small cell lung cancer: Canadian cancer trials group IND.196.
Oncotarget 2017 Jun . Leighl Natasha B, Tsao Ming-Sound, Liu Geoffrey, Tu Dongsheng, Ho Cheryl, Shepherd Frances A, Murray Nevin, Goffin John R, Nicholas Garth, Sakashita Shingo, Chen Zhuo, Kim Lucia, Powers Jean, Seymour Lesley, Goss Glenwood, Bradbury Penelope |
Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBACCA) nested within a compassionate use program.
BMC cancer 2016 16 412. Adenis Antoine, de la Fouchardiere Christelle, Paule Bernard, Burtin Pascal, Tougeron David, Wallet Jennifer, Dourthe Louis-Marie, Etienne Pierre-Luc, Mineur Laurent, Clisant Stéphanie, Phelip Jean-Marc, Kramar Andrew, Andre Thier |
From clinical trials to clinical practice: predictors of response to erlotinib in advanced non-small cell lung cancer patients pretreated with chemotherapy.
Tumori 0 97 (2): 160-5. Mazzoni Francesca, Rotella Virginia, Pratesi Nicola, Boni Luca, Simi Lisa, Orlando Claudio, Comin Camilla Eva, Maddau Cristina, Di Costanzo Frances |
- Page last reviewed:Oct 1, 2020
- Page last updated:Jan 15, 2021
- Content source: